188 related articles for article (PubMed ID: 35455984)
41. CSF flow patterns in the brain in patients with neuro-Behçet disease and Behçet disease.
Ünlü S; Doğan M; Kapicioğlu Y; Kamişli S; Öner S; Yildirim IO; Öztürk M
Eur Rev Med Pharmacol Sci; 2017 Oct; 21(17):3906-3910. PubMed ID: 28975972
[TBL] [Abstract][Full Text] [Related]
42. Neuro-Behçet's disease: an unusual cause of headache.
Fountain EM; Dhurandhar A
J Gen Intern Med; 2014 Jun; 29(6):956-60. PubMed ID: 24549519
[TBL] [Abstract][Full Text] [Related]
43. Magnetic resonance imaging and proton magnetic resonance spectroscopy in neuro-Behçet's disease.
Park KS; Ko HJ; Yoon CH; Park SH; Cho CS; Kim HY; Choe BY; Kim WU
Clin Exp Rheumatol; 2004; 22(5):561-7. PubMed ID: 15485008
[TBL] [Abstract][Full Text] [Related]
44. Upregulated IRAK1 and IRAK4 promoting the production of IFN-γ and IL-17 in Behcet's disease.
Sun M; Yang P; Yang Y; Ye J
Int Ophthalmol; 2018 Oct; 38(5):1947-1953. PubMed ID: 28780618
[TBL] [Abstract][Full Text] [Related]
45. Interleukin-23 Receptor Gene Polymorphism May Enhance Expression of the IL-23 Receptor, IL-17, TNF-α and IL-6 in Behcet's Disease.
Jiang Z; Hennein L; Tao Y; Tao L
PLoS One; 2015; 10(7):e0134632. PubMed ID: 26222305
[TBL] [Abstract][Full Text] [Related]
46. Lesion distribution pattern of parenchymal Neuro-Behçet's disease using probability mapping.
Emekli AS; Ersözlü E; Emekli MA; Gündüz T; Kürtüncü M
Mult Scler Relat Disord; 2022 Feb; 58():103457. PubMed ID: 34929453
[TBL] [Abstract][Full Text] [Related]
47. Severe neuro-Behcet's disease treated with a combination of immunosuppressives and a TNF-inhibitor.
Korkmaz FN; Ozen G; Ünal AU; Kahraman Koytak P; Tuncer N; Direskeneli H
Acta Reumatol Port; 2016; 41(4):367-371. PubMed ID: 27750273
[TBL] [Abstract][Full Text] [Related]
48. Increased expression of interleukin-23 p19 mRNA in erythema nodosum-like lesions of Behçet's disease.
Lew W; Chang JY; Jung JY; Bang D
Br J Dermatol; 2008 Mar; 158(3):505-11. PubMed ID: 18205865
[TBL] [Abstract][Full Text] [Related]
49. Neuro-Behcet's Disease Presenting as a Young Stroke.
Biniwale N; Kibe R; Biniwale A
J Assoc Physicians India; 2017 May; 65(5):89-90. PubMed ID: 28598056
[TBL] [Abstract][Full Text] [Related]
50. Role of IL-22- and TNF-α-producing Th22 cells in uveitis patients with Behcet's disease.
Sugita S; Kawazoe Y; Imai A; Kawaguchi T; Horie S; Keino H; Takahashi M; Mochizuki M
J Immunol; 2013 Jun; 190(11):5799-808. PubMed ID: 23630362
[TBL] [Abstract][Full Text] [Related]
51. Neuro-Behcet's syndrome: Case report and literature review.
Peine B; Figueroa C; Robinette N
Radiol Case Rep; 2022 Sep; 17(9):3064-3070. PubMed ID: 35769120
[TBL] [Abstract][Full Text] [Related]
52. Quality of life in neuro-Behçet's disease: a cross-sectional study.
Kuzu Kumcu M; Bakırarar B; Yücesan C
Neurol Sci; 2021 Mar; 42(3):1081-1086. PubMed ID: 32743747
[TBL] [Abstract][Full Text] [Related]
53. Atypical manifestations in Brazilian patients with neuro-Behçet's disease.
Dutra LA; Gonçalves CR; Braga-Neto P; Pedroso JL; Gabbai AA; Barsottini OG; de Souza AW
J Neurol; 2012 Jun; 259(6):1159-65. PubMed ID: 22169955
[TBL] [Abstract][Full Text] [Related]
54. Humoral immune response to mycobacterial heat shock protein (hsp)65 in the cerebrospinal fluid of neuro-Behçet patients.
Taşçi B; Direskeneli H; Serdaroglu P; Akman-Demir G; Eraksoy M; Saruhan-Direskeneli G
Clin Exp Immunol; 1998 Jul; 113(1):100-4. PubMed ID: 9697991
[TBL] [Abstract][Full Text] [Related]
55. Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease.
Niino M; Ogata A; Kikuchi S; Tashiro K; Nishihira J
J Neurol Sci; 2000 Oct; 179(S 1-2):127-31. PubMed ID: 11054496
[TBL] [Abstract][Full Text] [Related]
56. Pseudotumoural presentation of neuro-Behcet's disease: case series and review of literature.
Noel N; Hutié M; Wechsler B; Vignes S; Le Thi Huong-Boutin D; Amoura Z; Dormont D; Delcey V; Polivka M; Cacoub P; Saadoun D
Rheumatology (Oxford); 2012 Jul; 51(7):1216-25. PubMed ID: 22337940
[TBL] [Abstract][Full Text] [Related]
57. Toll-like receptor (TLR)7 and TLR9 agonists enhance interferon (IFN) beta-1a's immunoregulatory effects on B cells in patients with relapsing-remitting multiple sclerosis (RRMS).
Tao Y; Zhang X; Markovic-Plese S
J Neuroimmunol; 2016 Sep; 298():181-8. PubMed ID: 27609294
[TBL] [Abstract][Full Text] [Related]
58. Cytokines and chemokines in neuro-Behçet's disease compared to multiple sclerosis and other neurological diseases.
Saruhan-Direskeneli G; Yentür SP; Akman-Demir G; Işik N; Serdaroğlu P
J Neuroimmunol; 2003 Dec; 145(1-2):127-34. PubMed ID: 14644038
[TBL] [Abstract][Full Text] [Related]
59. Case Report: Repeated Low-Dose Rituximab Treatment Is Effective in Relapsing Neuro Behçet's Disease.
Zhao C; Li C; Duan FJ; Yan Q; Zhang Z; Du Y; Zhang W
Front Neurol; 2021; 12():595984. PubMed ID: 33935930
[TBL] [Abstract][Full Text] [Related]
60. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
